title: Effect ofBifidobacterium animalisssp.lactisGCL2505 on visceral fat accumulation in healthy Japanese adults: a randomized controlled trial.
abstract: Bifidobacterium animalisssp.lactisGCL2505 (B. lactisGCL2505) is able to survive passage through the intestine and then proliferate, leading to an increase in the amount of gut bifidobacteria. In the present study, we evaluated the impact ofB. lactisGCL2505 on abdominal visceral fat storage in overweight and mildly obese Japanese adults. This clinical study was a double-blind, randomized, placebo-controlled, parallel-group comparative trial performed for 12 weeks. Healthy Japanese subjects (N=137) with body mass indices ranging from 23 to 30 kg/m2consumed either fermented milk containingB. lactisGCL2505 or a placebo every day, and then visceral and subcutaneous abdominal fat areas were measured by computed tomography as the primary endpoints. The number of fecal bifidobacteria was also measured. Visceral fat area, but not subcutaneous fat area, was significantly reduced from baseline at 8 and 12 weeks in the GCL2505 group, compared with the placebo group. The total number of fecal bifidobacteria was significantly increased in the GCL2505 group. These results indicate thatB. lactisGCL2505 reduces abdominal visceral fat, a key factor associated with metabolic disorders. This finding suggests that this probiotic strain can potentially serve as a specific functional food to achieve visceral fat reduction in overweight or mildly obese individuals.
authors.affiliation: Institute of Health Sciences, Ezaki Glico Co., Ltd., 2-14-1 Musashino, Akishima-shi, Tokyo 196-0021, Japan.
authors.forename: Shota
authors.initials: S
authors.lastname: Takahashi
authors.affiliation: Institute of Health Sciences, Ezaki Glico Co., Ltd., 2-14-1 Musashino, Akishima-shi, Tokyo 196-0021, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Anzawa
authors.affiliation: Institute of Health Sciences, Ezaki Glico Co., Ltd., 2-14-1 Musashino, Akishima-shi, Tokyo 196-0021, Japan.
authors.forename: Kazuyo
authors.initials: K
authors.lastname: Takami
authors.affiliation: Institute of Health Sciences, Ezaki Glico Co., Ltd., 2-14-1 Musashino, Akishima-shi, Tokyo 196-0021, Japan.
authors.forename: Akihiro
authors.initials: A
authors.lastname: Ishizuka
authors.affiliation: Institute of Health Sciences, Ezaki Glico Co., Ltd., 2-14-1 Musashino, Akishima-shi, Tokyo 196-0021, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Mawatari
authors.affiliation: Institute of Health Sciences, Ezaki Glico Co., Ltd., 4-6-5 Utajima Nishiyodogawa, Osaka 555-8502, Japan.
authors.forename: Kohei
authors.initials: K
authors.lastname: Kamikado
authors.affiliation: Medical Corporation Shinkokai C'est lavie Shimbashi Clinic, 2-39-3 Nishishimbashi, Minato-ku, Tokyo 105-0003, Japan.
authors.forename: Haruhi
authors.initials: H
authors.lastname: Sugimura
authors.affiliation: Institute of Health Sciences, Ezaki Glico Co., Ltd., 2-14-1 Musashino, Akishima-shi, Tokyo 196-0021, Japan.
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Nishijima
keywords: Bifidobacterium; overweight; probiotics; randomized trial; visceral fat